Skip to content

Effects of Food Advanced Glycation Endproducts on Vascular Function in Diabetes

Acute Effects of Food Advanced Glycation Endproducts on Macrovascular Function in Subjects With Type 2 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01456026
Enrollment
19
Registered
2011-10-20
Start date
2009-06-30
Completion date
2010-05-31
Last updated
2011-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Keywords

Diabetes, Advanced glycation endproducts, Endothelium

Brief summary

Recent evidence supports detrimental effects of advanced glycation endproducts (AGE) on vascular function (VF). Though, the effect of AGE-modified proteins alone on vascular function remained unknown. Therefore, the aim of our study is to investigate the effects of heat-treated, glycated beta-lactoglobulins (BLG) on vascular function in subjects with type 2 diabetes mellitus (T2DM) and to compare it to non-glycated, heat-treated BLG.

Detailed description

In a double-blind, controlled, randomized, cross-over manner, 19 subjects with T2DM will receive on 2 different days beverages containing either glycated, heat-treated BLG or non-glycated, heat-treated BLG. Macrovascular (brachial ultrasound of flow mediated dilatation -FMD) and microvascular function (laser-doppler measurements of reactive hyperemia at the hand) at baseline (T0), as well as 90 (T90) and 180 (T180) minutes after each beverage will be measured.

Interventions

DIETARY_SUPPLEMENTGlycated beta-lactoglobulins.

oral, 20 g, single administration

DIETARY_SUPPLEMENTNon-glycated beta-lactoglobulins

20 g, oral, single administration,

Sponsors

Heart and Diabetes Center North-Rhine Westfalia
CollaboratorOTHER
Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
Profil Institut für Stoffwechselforschung GmbH
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes mellitus

Exclusion criteria

* Other types of diabetes * Major cardiovascular complications within 6 months prior to screening * Major diabetes complications * Failure to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Postprandial Change from Baseline in Flow Mediated DilatationBaseline, 90 and 180 min after oral intake of food AGEMacrovascular (brachial ultrasound of flow mediated dilatation -FMD) will be measured at baseline (T0), as well as 90 (T90) and 180 (T180) minutes after each beverage. The hypothesis of our study is that an AGE-rich beverage acutely impairs FMD more than a beverage with a low AGE content.

Secondary

MeasureTime frameDescription
Postprandial Change from Baseline in Microcirculation (Laser-Doppler measurements of reactive hyperemia at the hand)Baseline, 90 and 180 min. following food AGE intake.Microvascular function will be measured at baseline (T0), as well as 90 (T90) and 180 (T180) minutes after each beverage. The hypothesis of our study is that an AGE-rich beverage acutely impairs microvascular function more than a beverage with a low AGE content.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026